# Electroacupuncture Plus 5-HT3 Receptor Inhibitor for PONV Prevention in High-Risk Patients Undergoing Thoracoscopic Lung Cancer Surgery

> **NCT07515027** · NA · RECRUITING · sponsor: **Shanghai Chest Hospital** · enrollment: 204 (estimated)

## Conditions studied

- PONV

## Interventions

- **DRUG:** Prophylactic administration of dolasetron
- **OTHER:** Electroacupuncture
- **OTHER:** Sham electroacupuncture

## Key facts

- **NCT ID:** NCT07515027
- **Lead sponsor:** Shanghai Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-07
- **Primary completion:** 2026-11-01
- **Final completion:** 2026-12-31
- **Target enrollment:** 204 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07515027

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07515027, "Electroacupuncture Plus 5-HT3 Receptor Inhibitor for PONV Prevention in High-Risk Patients Undergoing Thoracoscopic Lung Cancer Surgery". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07515027. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*